Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11933652 | 0.85 | KEAP1 (0.43) | MAOBCES2CES1MAOAKEAP1 | |
| Hydrochloric Acid SCHEMBL1444088 | 0.83 | CES2 (0.44) | CES2CES1KEAP1MPO | |
| SCHEMBL27701683 | 0.83 | MAPK8 (0.44) | CES2CES1KEAP1MPOKMT2A | |
| SCHEMBL28776645 | 0.82 | HSP90AB1 (0.43) | CES2CES1KEAP1MPOALDH1A1 | |
| SCHEMBL17058842 | 0.82 | CES2 (0.40) | MAOBCES2CES1KEAP1DPP4 | |
| SCHEMBL26418173 | 0.79 | SLC6A4 (0.46) | MAOBCES2CES1MAOAHSD17B1 | |
| SCHEMBL11570 | 0.78 | CES2 (0.68) | MAOBCES2CES1MAOAKMT2A | |
| SCHEMBL29372550 | 0.78 | CES2 (0.68) | MAOBCES2CES1MAOAKMT2A | |
| SCHEMBL31293520 | 0.77 | NPC1 (0.40) | MAOBCES2CES1MAOAHSD17B1 | |
| SCHEMBL26418103 | 0.76 | HSD17B1 (0.40) | HSD17B1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | MAOB 60/4885CES2 92/4885CES1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.